ATC Group: N04BA01 Levodopa

The World Health Organization's ATC classification organizes medical drugs based on therapeutic properties, chemical composition, and anatomy. It helps make essential medicines readily available globally and is widely used in the pharmaceutical industry.

Position of N04BA01 in the ATC hierarchy

Level Code Title
1 N Nervous system
2 N04 Anti-parkinson drugs
3 N04B Dopaminergic agents
4 N04BA Dopa and dopa derivatives
5 N04BA01 Levodopa

Defined daily dose

The DDD is the assumed average maintenance dose per day for a drug used for its main indication in adults. The DDD is a unit of measurement and does not necessarily reflect the recommended or Prescribed Daily Dose. Therapeutic doses for individual patients and patient groups will often differ from the DDD as they will be based on individual characteristics (such as age, weight, ethnic differences, type and severity of disease) and pharmacokinetic considerations.

Route Amount
ORAL - Oral 3.5 g

Active ingredients in N04BA01

Active Ingredient Description
Levodopa

According to the current understanding, the symptoms of Parkinson’s disease are related to depletion of dopamine in the corpus striatum. Dopamine does not cross the blood-brain barrier. Levodopa, the precursor of dopamine, crosses the blood brain barrier and relieves the symptoms of the disease.

Related product monographs

Title Information Source Document Type  
INBRIJA Inhalation powder, capsule FDA, National Drug Code (US) MPI, US: SPL/PLR

Medicines in this ATC group

United States (US)

Austria (AT)

Estonia (EE)

Ireland (IE)

Japan (JP)

Lithuania (LT)

Poland (PL)

Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide.